Comparison Review
Reviewed by PeptidePrescriber Editorial Team.
This comparison is built for clinicians who need a practical prescribing conversation, not a social-media winner. The real question is which workflow, counseling burden, and product-status path your practice can support cleanly.
Mechanism
Semaglutide is a GLP-1 receptor agonist. Tirzepatide combines GIP and GLP-1 receptor agonism, which changes how many clinicians frame appetite, glycemic, and weight-loss expectations.
Administration
Both are once-weekly injectable workflows in common obesity and diabetes use cases, but concentration, device familiarity, titration scripts, and compounded-product error risk still need to be handled carefully.
When this belongs in practice
- Semaglutide can fit practices that want the simpler explanation path of a GLP-1-only mechanism and a longer period of real-world familiarity.
- Tirzepatide can fit practices that are comfortable explaining dual agonism, stronger efficacy expectations, and the operational demands of tighter titration counseling.
- The more important practice decision is often not which drug looks better in a headline. It is whether your clinic can explain product status, titration, adverse-effect counseling, and follow-up monitoring consistently.
Regulatory caution
This comparison gets riskier when the discussion slips from FDA-approved branded products into compounded semaglutide or compounded tirzepatide. Practices should separate approved-product counseling from compounded-product counseling and document that distinction clearly.
Starter Pack
Turn this guide into a repeatable clinical workflow.
Use the starter pack, consent packet, and implementation checklist to move from reading into a cleaner operational system.